Two companies based in Asia have unveiled unexpected delays to the progress of key clinical-stage pipeline assets, and although analysts do not appear to be too concerned at this stage about the longer-term implications, the companies say there will be some impact and further updates are awaited as the events are analysed further.
ASLAN, Sosei Pipeline Assets Hit By Development Delays
Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.
